A combination of the CDK 4/6 inhibitor abemaciclib with fulvestrant improved overall survival (OS) in patients with HR+, HER2- advanced breast cancer (ABC), with a trend toward improved outcomes in patients with poor prognosis, according to results of the phase III MONARCH 2* trial presented at ESMO 2019.
Drugs used to modify blood glucose and lipid levels appear to help slow the progression of chronic kidney disease (CKD), suggesting that glycaemic control and lipid regulation may improve renal function in patients with moderate CKD, according to a systematic review and meta-analysis.
Preliminary real-world findings of the REALITI-A* study, presented at ERS 2019, have demonstrated a significant reduction in asthma exacerbations with mepolizumab, a result comparable to that of regulatory clinical trials with this drug.
Treatment with the novel acid secretion inhibitor vonoprazan at 10 mg effectively maintains remission through 52 weeks in patients with proton pump inhibitor (PPI)-resistant reflux oesophagitis, according to the results of a trial from Japan.
Having elevated blood eosinophil counts (BEC) along with three other clinical characteristics help identify a subgroup of patients with COPD* who are most likely to benefit from benralizumab in terms of exacerbation reduction, according to a prespecified pooled analysis of the phase III GALATHEA and TERRANOVA** trials.
The use of low-dose indacaterol acetate/mometasone furoate (IND/MF), a long-acting β2-agonist/inhaled corticosteroid (LABA/ICS) combination, significantly improves trough FEV1* in symptomatic patients with poorly controlled asthma, according to the QUARTZ** study presented at ERS 2019.
The use of single-inhaler triple therapy yields meaningful improvements across a range of chronic obstructive pulmonary disease (COPD) endpoints over time compared with dual therapies, according to data from the IMPACT* trial presented at the 2019 European Respiratory Society (ERS) International Congress.
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.
A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.